Market conditions put paid to Salient IPO
This article was originally published in Clinica
Executive Summary
Salient Surgical Technologies has withdrawn its pending initial public offering (IPO) on the grounds of unfavourable market conditions. The surgical products specialist had intended to list on the Nasdaq Stock Exchange after filing an IPO on March 13 2008 (see Clinica No 1299, p 17). Salient was looking to raise $86m to boost development of its Aquamantys system, which is designed to seal blood vessels in soft tissue and bone. The Dover, New Hampshire company becomes the fourth medtech company this year to pull an IPO from the Nasdaq because of market conditions. The preceding firms were: Transoma Medical (see Clinica 1294, p 15), Emphasys Medical (see Clinica No 1307, p 24) and Bronchus Technologies, which cancelled its IPO in June.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals